Propanc Biopharma issues $33,750 convertible note with 35% discount for working capital

Propanc Biopharma, Inc.

Issued convertible promissory note to 104 LLC for gross proceeds of $30,375 after $2,500 legal fee deduction.
Note matures June 20, 2025, bears 10% interest (16% on default), convertible at 65% of lowest closing price over prior 10 days.
Company can prepay at premiums 110-125% of face within first 180 days; no prepayment right after.
Net proceeds used for general working capital; issued under Section 4(a)(2)/Rule 506(b) exemption.
Conversion shares subject to 4.99% beneficial ownership limitation and 500% reserve requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.